UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

摘要 北卡罗来纳大学教堂山分校(UNC)与杜克大学合作取得了成功 T32临床药理学博士后培训计划，以我们的卓越研究为基础 在药物发现、药物开发、药代动力学方面拥有世界级计划的环境/ 药效学、儿科临床药理学和药物安全性。对临床药师的需求 是高的，我们在培训临床医生和科学家以满足不断增长的劳动力方面有着出色的记录 这一领域的需求。我们有一个优秀和多样化的申请者人才库，比 有资金的职位。此续订申请(11-15年)描述了我们的2年期培训计划(4个新的 实习生/年)，它提供强大的领导力，来自多个学科的国际公认的导师 积极参与临床药理学，广泛的尖端技术和资源，以及 独特的协作环境和强有力的制度支持。这一项目的全国申请者池 该计划主要来源于医学专业培训计划中寻求临床职业道路的医学博士 药理学以及药学专业的高级临床/转化性研究培训。受训人员，由 个性化的发展计划和指导团队，完成临床药理学课程和 参与特定项目的活动，以获得当代临床药理学各方面的专业知识 研究为成功的学术、监管或行业职业生涯做准备，成为 未来几代临床药理学家。经验丰富的教师导师是根据他们的 在构成本培训计划核心的四个重点领域中至少一个领域的研究效率：药物 处置和行动；定量药理学/药物计量学和临床试验设计；个体化 治疗；药物引起的器官毒性。该培训计划的新内容包括更多关注 在精确剂量、使用真实数据和药物计量学方面；扩大临床试验计划 专业和创新领域的药理学培训；增加职业发展机会； 以及扩大与其他T32计划的合作。这一培训计划的一个独特之处在于 将重点放在临床药理学研究不足的领域，特别是儿科和药物安全性。这个 在我们的实习生群体中对临床药理学产生了浓厚的兴趣，在临床方面的投资是无与伦比的 北卡罗来纳大学和杜克大学的药理学研究资源，智力丰富的生物医学科学环境 研究三角园区和我们长期优秀的研究和培训基础设施相结合，创造了 无与伦比的临床药理学培训机会。

ABSTRACT The University of North Carolina at Chapel Hill (UNC) in collaboration with Duke University has a successful T32 postdoctoral training program in clinical pharmacology that builds on our exceptional research environment with world-class programs in drug discovery, drug development, pharmacokinetics/ pharmacodynamics, pediatric clinical pharmacology, and drug safety. The demand for clinical pharmacologists is high, and we have an outstanding track record of training clinician-scientists to meet the growing workforce needs in this field. We have an excellent and diverse applicant pool with many more qualified applicants than funded positions. This renewal application (Years 11-15) describes our 2-year training program (4 new trainees/year), which offers strong leadership, internationally-recognized mentors from multiple disciplines who are actively involved in clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program is derived primarily from MDs in medical specialty training programs seeking a career path in clinical pharmacology, and also from PharmDs in advanced clinical/translational research training. Trainees, guided by individualized development plans and mentoring teams, complete clinical pharmacology coursework and engage in program-specific activities to gain expertise in all aspects of contemporary clinical pharmacology research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to future generations of clinical pharmacologists. Experienced faculty mentors are chosen based on their research productivity in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design; Individualized Therapy; Drug-induced Organ Toxicity. New components of this training program include an increased focus on precision dosing, use of real-world data, and pharmacometrics; pilot programs to expand clinical pharmacology training in specialty and innovative areas; enhanced professional development opportunities; and expansion of collaborations with other T32 programs. A unique feature of this training program continues to be our focus on understudied areas in clinical pharmacology, specifically pediatrics and drug safety. The keen interest in clinical pharmacology within our trainee pool, the unparalleled investment in clinical pharmacology research resources at UNC and Duke, the intellectually-rich biomedical science environment of Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in clinical pharmacology.